<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042702</url>
  </required_header>
  <id_info>
    <org_study_id>CTIX-KEV-201</org_study_id>
    <nct_id>NCT03042702</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer</brief_title>
  <official_title>A Phase 2 Study of Kevetrin (Thioureidobutyronitrile) in Subjects With Platinum-Resistant/Refractory Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovation Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovation Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cellceutix has developed Kevetrin (thioureidobutyronitrile), belonging to an&#xD;
      anti-proliferative p53 activator pharmacological class, for the treatment of cancer.&#xD;
      Nonclinical studies have demonstrated that Kevetrin induces apoptosis by activation of wild&#xD;
      type p53 and induces apoptosis in mutant p53 cells by degradation of oncogenic mutant p53.&#xD;
&#xD;
      In this Phase 2 study, two different short-term treatment regimens of Kevetrin will be&#xD;
      evaluated for safety, tolerability, changes in biomarkers/objective tumor response, and to&#xD;
      evaluate the pharmacokinetics of Kevetrin when administered to subjects with&#xD;
      platinum-resistant/refractory ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, dose-escalation trial to study the safety, biomarker changes&#xD;
      (including modulation of p53), objective tumor response changes, and pharmacokinetics&#xD;
      following administration of two different treatment regimens of Kevetrin over a 3-week period&#xD;
      to subjects with platinum-resistant/refractory ovarian cancer. Following the 3 weeks of&#xD;
      Kevetrin dosing, subjects are to be followed up for 3 weeks after completion of Kevetrin&#xD;
      treatment. Standard of care treatment, as medically appropriate and per local guidelines,&#xD;
      outside of this study protocol can commence after the collection of the post-Kevetrin&#xD;
      treatment biomarker samples (collected on Day 21±1 day). The patient population recruited&#xD;
      into this study includes those ovarian cancer patients that have platinum&#xD;
      resistant/refractory disease, defined as disease progression/relapse within 6 months&#xD;
      following the last administered dose of platinum therapy (resistant), or lack of response or&#xD;
      disease progression while receiving the most recent platinum based therapy (refractory),&#xD;
      respectively. Patients may or may not have had additional treatment (e.g., Doxil) prior to&#xD;
      entry in this study.&#xD;
&#xD;
      A total of approximately 10 study participants are planned to be enrolled in two cohorts of&#xD;
      approximately 5 subjects per cohort, with enrollment in a sequential, dose-escalating&#xD;
      fashion. Investigators and subjects will be aware of the treatment cohort into which they are&#xD;
      recruiting. Cohort details and the planned doses are:&#xD;
&#xD;
      Cohort 1 (n=5) Kevetrin Cycle - Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3&#xD;
      doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses); Follow-up for&#xD;
      3 weeks after Kevetrin treatment ends Cohort 2 (n=5) Kevetrin Cycle - Kevetrin 350 mg/m2 IV&#xD;
      per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks&#xD;
      (single cycle; total 9 doses); Follow-up for 3 weeks after Kevetrin treatment ends Cohorts 1&#xD;
      and 2 will be conducted in a sequential fashion, with safety data from cohort 1 evaluated by&#xD;
      an independent Data Monitoring Committee (DMC). The DMC will make appropriate recommendations&#xD;
      based on the available safety data as regards the intent of progressing to the higher dose&#xD;
      cohort 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2017</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">November 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Reporting of Adverse Events, and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Changes in Biomarkers</measure>
    <time_frame>3 Weeks</time_frame>
    <description>Changes in RNA and/or protein level of pre-specified biomarkers associated with the p53 signalling pathway and apoptosis will be compared between pre-treatment sample (tumor biopsy, ascites fluid, and peripheral blood) and post-treatment sample (tumor biopsy, ascites fluid, and peripheral blood)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants by RECIST Tumor Response Category</measure>
    <time_frame>3 Weeks</time_frame>
    <description>Number of subjects in each response category (complete response, partial response, stable disease or progressive disease) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.&#xD;
CR (Complete Response): Disappearance of all target lesions PR (Partial Response) : At least a 30% decrease in the sum of the longest diameters of target lesions PD (Progressive Disease) : At least a 20% increase in the sum of the longest diameters of target lesions SD (Stable Disease) : Small changes that do not meet above criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of Kevetrin (Cmax) on Days 1 and 5</measure>
    <time_frame>Prior to dosing, During 3h infusion: 60(±5) min, 120(±5) min, and 2 min prior to end of infusion, i.e., 178 min. Post infusion: 0.5 hour (±5 min), 1 hour (±5 min), 2 hour (±5 min), 4 hour (±10 mins), 6 hour (±30 mins) [optional], and 24(±4) hour</time_frame>
    <description>Measurement of Kevetrin systemic concentrations from collected blood samples. Due to low number of subjects individual values are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration of Kevetrin (Tmax) on Days 1 and 5</measure>
    <time_frame>Prior to dosing, During 3h infusion: 60(±5) min, 120(±5) min, and 2 min prior to end of infusion, i.e., 178 min. Post infusion: 0.5 hour (±5 min), 1 hour (±5 min), 2 hour (±5 min), 4 hour (±10 mins), 6 hour (±30 mins) [optional], and 24(±4) hour</time_frame>
    <description>Measurement of Kevetrin systemic concentrations from collected blood samples. Due to low number of subjects individual values are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUCt) on Days 1 and 5</measure>
    <time_frame>Prior to dosing, During 3h infusion: 60(±5) min, 120(±5) min, and 2 min prior to end of infusion, i.e., 178 min. Post infusion: 0.5 hour (±5 min), 1 hour (±5 min), 2 hour (±5 min), 4 hour (±10 mins), 6 hour (±30 mins) [optional], and 24(±4) hour</time_frame>
    <description>Measurement of Kevetrin systemic concentrations from collected blood samples. Due to low number of subjects individual values are presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Kevetrin 250 mg/m2 IV Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kevetrin 350 mg/m2 IV Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kevetrin</intervention_name>
    <description>Kevetrin dose to associated cohort</description>
    <arm_group_label>Kevetrin 250 mg/m2 IV Cohort 1</arm_group_label>
    <other_name>Cohort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kevetrin</intervention_name>
    <description>Kevetrin dose to associated cohort</description>
    <arm_group_label>Kevetrin 350 mg/m2 IV Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Evidence of a personally signed and dated written informed consent to participate in&#xD;
             the clinical study&#xD;
&#xD;
          2. Non-pregnant female adults at least 18 years of age at time of informed consent&#xD;
&#xD;
          3. Histologically confirmed serous epithelial ovarian cancer with peritoneal metastases&#xD;
&#xD;
          4. Platinum resistant/refractory disease, defined as disease progression/relapse within 6&#xD;
             months following the last administered dose of platinum therapy (resistant), or lack&#xD;
             of response or disease progression while receiving the most recent platinum based&#xD;
             therapy (refractory), respectively&#xD;
&#xD;
          5. Measurable disease, as determined by radiologist evaluator, with at least 1&#xD;
             unidimensional measurable lesion (target lesion) by RECIST v.1.1 that has not&#xD;
             previously been irradiated or biopsied&#xD;
&#xD;
          6. Presence of non-target lesions that have not previously been irradiated or biopsied;&#xD;
             to allow for collection of needle-biopsies at Screening and after completion of&#xD;
             Kevetrin treatment&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          8. Adequate hematologic and organ function as confirmed by laboratory values at&#xD;
             Screening:&#xD;
&#xD;
               1. Bone marrow function: Absolute neutrophil count (ANC) ≥ 1500 Cells/μL (with no&#xD;
                  evidence that this ANC was induced or supported by granulocyte colony stimulating&#xD;
                  factors)&#xD;
&#xD;
               2. Hemoglobin ≥ 9 g/dL (with no RBC transfusions within 7 days of Screening)&#xD;
&#xD;
               3. Platelets ≥ 100,000 cells/μL (with no evidence that this platelet count was&#xD;
                  induced or supported by a platelet-stimulating agent)&#xD;
&#xD;
               4. Renal function: creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               5. Hepatic function: total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 3 x ULN; alkaline&#xD;
                  phosphatase ≤ 2.5 x ULN&#xD;
&#xD;
               6. Neurologic function: neuropathy (sensory and motor) ≤ CTCAE Grade 1&#xD;
&#xD;
               7. Coagulation status: prothrombin time (PT) ≤ 1.5 ULN or INR within normal limits;&#xD;
                  and partial thromboplastin time (PTT) ≤ 1.2 × ULN&#xD;
&#xD;
          9. Women of child-bearing potential are required to use effective contraception&#xD;
             throughout the study period. Effective contraception methods include:&#xD;
&#xD;
               1. Total abstinence (if this is the usual lifestyle of the subject). Periodic&#xD;
                  abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and&#xD;
                  withdrawal are not acceptable methods of contraception. (Subject must agree to&#xD;
                  use contraception should they become sexually active while on the study.)&#xD;
&#xD;
               2. Surgical sterilization (hysterectomy and/or bilateral oophorectomy) or tubal&#xD;
                  ligation at least six weeks before start of study treatment.&#xD;
&#xD;
               3. Male partner sterilization, occurring at least 6 months prior to screening. For&#xD;
                  female subjects on the study, the vasectomized male partner should be their sole&#xD;
                  partner.&#xD;
&#xD;
               4. Double barrier method: Condom or Occlusive cap (diaphragm or cervical/vault caps)&#xD;
                  with spermicidal foam/gel/film/cream/vaginal suppository.&#xD;
&#xD;
               5. Oral*/ injected/ implanted/ transdermal hormonal contraception or other forms of&#xD;
                  hormonal contraception that have comparable efficacy (failure rate &lt;1%), e.g.,&#xD;
                  hormone vaginal ring.&#xD;
&#xD;
               6. Intrauterine device or intrauterine system. *Stable oral contraception use (on&#xD;
                  the same pill) for a minimum of 3 months before taking study treatment.&#xD;
&#xD;
             Women are considered post-menopausal and not of child-bearing potential if they have&#xD;
             had 12 consecutive months of natural (spontaneous) amenorrhea with an appropriate&#xD;
             clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had&#xD;
             surgical hysterectomy and/or bilateral oophorectomy or tubal ligation at least six&#xD;
             weeks ago.&#xD;
&#xD;
         10. Estimated life expectancy of at least 6 months, in the Investigator's opinion&#xD;
&#xD;
         11. Willing and able to comply with scheduled visits, study assessments and laboratory&#xD;
             tests, and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwilling to allow removal of tumor biological samples for analysis, i.e., biopsies of&#xD;
             tumor lesions, and/or collection of ascites fluid from abdominal ascites (if present)&#xD;
&#xD;
          2. Non epithelial tumor, including malignant mixed Müllerian tumors without high grade&#xD;
             serous component, or ovarian tumors with low malignant potential (i.e., borderline&#xD;
             tumors)&#xD;
&#xD;
          3. Known presence of central nervous system metastases&#xD;
&#xD;
          4. Presence of tumor metastases causing significant pleural disease/effusion unilaterally&#xD;
             or bilaterally (significant pleural effusion is defined by need for thoracentesis more&#xD;
             frequently than once every 21 days)&#xD;
&#xD;
          5. Presence of ascites that requires paracentesis more frequently than once every 21&#xD;
             days.&#xD;
&#xD;
          6. A history of another primary cancer that has been active or treated within the past 3&#xD;
             years prior to start of study treatment, with the exception of adequately&#xD;
             treated/resected: basal cell or squamous cell skin carcinoma or actinic keratoses; or&#xD;
             carcinoma in situ of the breast or of the cervix; or non-invasive malignant colon&#xD;
             polyps&#xD;
&#xD;
          7. Persistent toxic effects with severity of CTCAE grade 2 or greater (excluding&#xD;
             alopecia) caused by previous treatment&#xD;
&#xD;
          8. History of arterial or deep venous thromboembolism within the 12 months prior to&#xD;
             enrollment&#xD;
&#xD;
          9. Clinically significant cardiac disease, including:&#xD;
&#xD;
               1. Myocardial infarction or unstable angina &lt; 6 months prior to enrollment&#xD;
&#xD;
               2. New York Heart Association (NYHA) Grade II or greater congestive heart failure&#xD;
&#xD;
               3. Cardiac arrhythmia requiring medication (does not include asymptomatic atrial&#xD;
                  fibrillation with controlled ventricular rate)&#xD;
&#xD;
         10. Electrocardiogram (ECG) obtained at Screening which shows QTc prolongation or other&#xD;
             medically relevant abnormalities which may affect subject safety or interpretation of&#xD;
             study results&#xD;
&#xD;
         11. At a higher than average risk, in the Investigator's opinion, of bowel perforation&#xD;
             (e.g., symptoms of partial or complete bowel obstruction, recent (within 6 months)&#xD;
             history of fistula or bowel perforation, requirement for total parenteral nutrition&#xD;
             and continuous hydration)&#xD;
&#xD;
         12. Active or chronic recurrent systemic infections that require continuous antimicrobial&#xD;
             therapy during the Kevetrin study period&#xD;
&#xD;
         13. Past medical history of infection with HIV, hepatitis B or hepatitis C&#xD;
&#xD;
         14. Ongoing or recent history of any other uncontrolled and/or clinically significant&#xD;
             systemic disease or condition which, in the Investigator's medical opinion, should&#xD;
             exclude participation in the study&#xD;
&#xD;
         15. Less than 3 weeks between major surgery and planned start of study treatment; major&#xD;
             incisions must have healed&#xD;
&#xD;
         16. Less than 4 weeks since last treatment for ovarian cancer&#xD;
&#xD;
         17. Any investigational or experimental therapy or procedure or participation in any&#xD;
             interventional trial within 4 weeks or 5 half-lives (whichever is longer) prior to&#xD;
             start of study treatment&#xD;
&#xD;
         18. Women of child-bearing potential who are pregnant or nursing (lactating)&#xD;
&#xD;
         19. Previous participation in a clinical study of Kevetrin&#xD;
&#xD;
         20. History of alcohol or substance abuse, unless in full remission for more than 6 months&#xD;
             prior to start of study treatment&#xD;
&#xD;
         21. Any other severe acute or chronic medical or psychiatric condition or test&#xD;
             abnormality(ies) that, in the Investigator's opinion, puts the subject at significant&#xD;
             risk, could confound the study results, or may interfere significantly with the&#xD;
             subject's participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Bertolino, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cellceutix Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Research</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <results_first_submitted>November 6, 2018</results_first_submitted>
  <results_first_submitted_qc>December 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 27, 2018</results_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03042702/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No participants were enrolled in the &quot;Kevetrin 350 mg/m2 IV&quot;/&quot;Cohort 2&quot; Arm/Group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Kevetrin 250 mg/m2 IV/Cohort 1</title>
          <description>Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends&#xD;
Kevetrin: Kevetrin dose to associated cohort</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Kevetrin 250 mg/m2 IV/Cohort 1</title>
          <description>Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends&#xD;
Kevetrin: Kevetrin dose to associated cohort</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>54 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>71 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events</title>
        <description>Reporting of Adverse Events, and severity of adverse events</description>
        <time_frame>6 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kevetrin 250 mg/m2 IV/Cohort 1</title>
            <description>Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends&#xD;
Kevetrin: Kevetrin dose to associated cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events</title>
          <description>Reporting of Adverse Events, and severity of adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Changes in Biomarkers</title>
        <description>Changes in RNA and/or protein level of pre-specified biomarkers associated with the p53 signalling pathway and apoptosis will be compared between pre-treatment sample (tumor biopsy, ascites fluid, and peripheral blood) and post-treatment sample (tumor biopsy, ascites fluid, and peripheral blood)</description>
        <time_frame>3 Weeks</time_frame>
        <population>All</population>
        <group_list>
          <group group_id="O1">
            <title>Kevetrin 250 mg/m2 IV/Cohort 1</title>
            <description>Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends&#xD;
Kevetrin: Kevetrin dose to associated cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes in Biomarkers</title>
          <description>Changes in RNA and/or protein level of pre-specified biomarkers associated with the p53 signalling pathway and apoptosis will be compared between pre-treatment sample (tumor biopsy, ascites fluid, and peripheral blood) and post-treatment sample (tumor biopsy, ascites fluid, and peripheral blood)</description>
          <population>All</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Observed biomarker changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No observed biomarker changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants by RECIST Tumor Response Category</title>
        <description>Number of subjects in each response category (complete response, partial response, stable disease or progressive disease) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.&#xD;
CR (Complete Response): Disappearance of all target lesions PR (Partial Response) : At least a 30% decrease in the sum of the longest diameters of target lesions PD (Progressive Disease) : At least a 20% increase in the sum of the longest diameters of target lesions SD (Stable Disease) : Small changes that do not meet above criteria</description>
        <time_frame>3 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kevetrin 250 mg/m2 IV Cohort 1</title>
            <description>Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends&#xD;
Kevetrin: Kevetrin dose to associated cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by RECIST Tumor Response Category</title>
          <description>Number of subjects in each response category (complete response, partial response, stable disease or progressive disease) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.&#xD;
CR (Complete Response): Disappearance of all target lesions PR (Partial Response) : At least a 30% decrease in the sum of the longest diameters of target lesions PD (Progressive Disease) : At least a 20% increase in the sum of the longest diameters of target lesions SD (Stable Disease) : Small changes that do not meet above criteria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration of Kevetrin (Cmax) on Days 1 and 5</title>
        <description>Measurement of Kevetrin systemic concentrations from collected blood samples. Due to low number of subjects individual values are presented.</description>
        <time_frame>Prior to dosing, During 3h infusion: 60(±5) min, 120(±5) min, and 2 min prior to end of infusion, i.e., 178 min. Post infusion: 0.5 hour (±5 min), 1 hour (±5 min), 2 hour (±5 min), 4 hour (±10 mins), 6 hour (±30 mins) [optional], and 24(±4) hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kevetrin 250 mg/m2 IV Cohort 1</title>
            <description>Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends&#xD;
Kevetrin: Kevetrin dose to associated cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration of Kevetrin (Cmax) on Days 1 and 5</title>
          <description>Measurement of Kevetrin systemic concentrations from collected blood samples. Due to low number of subjects individual values are presented.</description>
          <units>ng/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject 002-001 Cmax Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 002-001 Cmax Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 002-002 Cmax Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 002-002 Cmax Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Plasma Concentration of Kevetrin (Tmax) on Days 1 and 5</title>
        <description>Measurement of Kevetrin systemic concentrations from collected blood samples. Due to low number of subjects individual values are presented.</description>
        <time_frame>Prior to dosing, During 3h infusion: 60(±5) min, 120(±5) min, and 2 min prior to end of infusion, i.e., 178 min. Post infusion: 0.5 hour (±5 min), 1 hour (±5 min), 2 hour (±5 min), 4 hour (±10 mins), 6 hour (±30 mins) [optional], and 24(±4) hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kevetrin 250 mg/m2 IV Cohort 1</title>
            <description>Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends&#xD;
Kevetrin: Kevetrin dose to associated cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Plasma Concentration of Kevetrin (Tmax) on Days 1 and 5</title>
          <description>Measurement of Kevetrin systemic concentrations from collected blood samples. Due to low number of subjects individual values are presented.</description>
          <units>hours</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject 002-001 Tmax Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 002-001 Tmax Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 002-002 Tmax Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 002-002 Tmax Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUCt) on Days 1 and 5</title>
        <description>Measurement of Kevetrin systemic concentrations from collected blood samples. Due to low number of subjects individual values are presented.</description>
        <time_frame>Prior to dosing, During 3h infusion: 60(±5) min, 120(±5) min, and 2 min prior to end of infusion, i.e., 178 min. Post infusion: 0.5 hour (±5 min), 1 hour (±5 min), 2 hour (±5 min), 4 hour (±10 mins), 6 hour (±30 mins) [optional], and 24(±4) hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kevetrin 250 mg/m2 IV Cohort 1</title>
            <description>Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends&#xD;
Kevetrin: Kevetrin dose to associated cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUCt) on Days 1 and 5</title>
          <description>Measurement of Kevetrin systemic concentrations from collected blood samples. Due to low number of subjects individual values are presented.</description>
          <units>hours*ng/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject 002-001 AUCt Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 002-001 AUCt Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 002-002 AUCt Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 002-002 AUCt Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from Screening thru End of Study. approximately 6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends&#xD;
Kevetrin: Kevetrin dose to associated cohort</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arthur P. Bertolino MD, PhD, MBA</name_or_title>
      <organization>Innovation Pharmaceuticals</organization>
      <phone>9789214125</phone>
      <email>abertolino@IPharmInc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

